For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

ARS Pharmaceuticals (NASDAQ:SPRY) has signed a four-year agreement with ALK-Abelló A/S to co-promote neffy, its epinephrine ...

ARS Pharmaceuticals (NASDAQ:SPRY) partners with ALK to co-promote neffy, an epinephrine nasal spray, to 9,000 pediatricians.